Metastatic HR+/HER2- Breast Cancer Market Report 2026

The metastatic hr+/her2- breast cancer market size has grown strongly in recent years. It will grow from $10.89 billion in 2025 to $11.97 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to rising breast cancer prevalence, adoption of hormonal therapies, increased chemotherapy usage, development of early diagnostic tools, improved survival monitoring.

The metastatic hr+/her2- breast cancer market size is expected to see strong growth in the next few years. It will grow to $17.26 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to growth in targeted therapies like cdk4/6 inhibitors, expanding immunotherapy research, increasing use of genomic profiling, rising demand for combination regimens, enhanced patient monitoring technologies. Major trends in the forecast period include precision hormonal therapy advancements, AI-enhanced treatment personalization, data-driven monitoring of treatment response, virtual simulation for oncology training, automated diagnostic workflow integration.

The rising use of hormone replacement therapy (HRT) is expected to drive the growth of the metastatic HR+/HER2- breast cancer market in the coming years. Hormone replacement therapy (HRT) is a medical intervention designed to supplement or replace hormones that are at lower levels in the body, most commonly during menopause or in cases of hormone deficiencies. The growing adoption of hormone replacement therapy (HRT) is attributed to its effectiveness in improving treatment outcomes, lower side effects compared to conventional therapies, and advancements in precision medicine. Hormone replacement therapy (HRT) can support metastatic HR+/HER2- breast cancer by alleviating symptoms of estrogen deficiency associated with menopause, such as hot flashes and vaginal dryness, without affecting the efficacy of endocrine therapies, as it primarily addresses hormone imbalances rather than targeting cancer cells, thereby ensuring an improved quality of life for patients undergoing cancer treatment. For example, in October 2023, the Health Professional Academy, a UK-based personalized health professional learning platform, reported that in 2022/23, nearly 11 million hormone replacement therapy (HRT) prescriptions were issued, reflecting an almost 50% increase from the previous year. Consequently, the rising use of hormone replacement therapy (HRT) is driving the metastatic HR+/HER2- breast cancer market.

Major companies operating in the metastatic HR+/HER2- breast cancer market are focusing on developing combination therapies to broaden their indications, market presence, and treatment options. Combination therapy is a treatment strategy that involves using two or more therapeutic agents simultaneously, which may include chemotherapy, targeted therapy, immunotherapy, hormone therapy, or other modalities, to manage a medical condition more effectively by targeting multiple pathways, enhancing overall treatment response, and minimizing the chance of the condition, such as cancer, developing resistance to a single treatment. For example, in July 2023, Merck & Co., Inc., a US-based pharmaceutical company, announced the Phase 3 KEYNOTE-756 trial evaluating KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, in combination with FDA-approved chemotherapy. The trial achieved its primary endpoint by significantly improving the pathological complete response (pCR) rate in patients with high-risk, early-stage ER+/HER2- breast cancer. KEYNOTE-756 represents the first positive Phase 3 trial demonstrating a statistically significant improvement in pCR rate with an immunotherapy regimen in the neoadjuvant setting for this patient population. The trial evaluated KEYTRUDA with chemotherapy as a neoadjuvant treatment, followed by adjuvant KEYTRUDA combined with endocrine therapy for high-risk, early-stage ER+/HER2- breast cancer.

In November 2023, Carrum Health, a US-based healthcare solutions provider, collaborated with Texas Oncology to deliver breast cancer treatment. Through this partnership, Carrum Health intends to offer patients a bundled breast cancer care package, covering two years of chemotherapy, radiation, and symptom management provided by Texas Oncology, aiming to ensure high-quality, cost-effective care. Texas Oncology is a US-based company specializing in treatment for metastatic HR+/HER2- breast cancer.

Major companies operating in the metastatic hr+/her2- breast cancer market are Pfizer Inc., F Hoffmann‑La Roche AG, AstraZeneca PLC, Eli Lilly and Company, Merck & Co, Arvinas Inc, Olema Pharmaceuticals Inc, Genentech Inc, Veru Pharma, DualityBio Inc, BioNTech SE, Evgen Pharma, EQRx Inc, G1 Therapeutics Inc, Immutep Ltd, RemeGen Co Ltd, SynCore Biotechnology Co Ltd, Allarity Therapeutics AS, Jiangsu Alphamab Biopharmaceuticals Co Ltd, Byondis BV, Jiangsu Hansoh Pharmaceutical Co Ltd, Shanghai Miracogen Inc, Eisai Co Ltd, Tyme Inc, Orion Pharma.

North America was the largest region in the dominated market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic hr+/her2- breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metastatic hr+/her2- breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on pharmaceutical ingredients, oncology drugs, and diagnostic equipment have increased manufacturing and distribution costs, slowing access to therapies in import-dependent regions such as Asia-Pacific and Latin America. These tariffs particularly affect the availability of targeted therapies and hormonal treatment formulations. However, tariffs have encouraged local drug production and innovation, potentially leading to long-term supply chain resilience and reduced dependency on foreign suppliers.

The metastatic hr+/her2- breast cancer market research report is one of a series of new reports that provides metastatic hr+/her2- breast cancer market statistics, including metastatic hr+/her2- breast cancer industry global market size, regional shares, competitors with a metastatic hr+/her2- breast cancer market share, detailed metastatic hr+/her2- breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic hr+/her2- breast cancer industry. This metastatic hr+/her2- breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Metastatic HR+/HER2- breast cancer is a type of breast cancer in which the cancer cells have spread from the breast to other areas of the body. Treatment for metastatic HR+/HER2- breast cancer involves the use of targeted therapies, hormonal treatments, and chemotherapy to control disease progression and enhance patient outcomes.

The primary drugs used in metastatic HR+/HER2- breast cancer include paclitaxel, tamoxifen, vinblastine, raloxifene, docetaxel, and other medications. Paclitaxel is a chemotherapy agent that suppresses cancer cell growth by stabilizing microtubules, thereby inhibiting cell division. Treatments may also involve radiation therapy, vitamin therapy, macrobiotic diets, homeopathy, and herbal remedies, and are utilized by various end users, including hospitals, clinics, and other healthcare providers.

The metastatic HR+/HER2- breast cancer market consists revenues earned by entities by providing services such as endocrine therapy, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic HR+/HER2- breast cancer market also includes sales of CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors, and chemotherapy agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.